Oxidative stress-mediated destruction of normal parenchymal cells during hepatic inflammatory responses contributes to the pathogenesis of immune-mediated hepatitis and is implicated in the progression of acute inflammatory liver injury to chronic inflammatory liver disease. The transcription factor NF-E2-related factor 2 (Nrf2) regulates the expression of a battery of antioxidative enzymes and Nrf2 signaling can be activated by small-molecule drugs that disrupt Keap1-mediated repression of Nrf2 signaling. Therefore, genetic and pharmacologic approaches were used to activate Nrf2 signaling to assess protection against inflammatory liver injury. Profound increases in ind of cell death were observed in both Nrf2 wild-type (Nrf2-WT) mice and Nrf2- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Introduction
While acute inflammatory responses to pathogen infection and tissue injury are necessary for survival, sustained immune responses can result in damage to non-target cells that are neither infected nor damaged by the initial chemical or physical insult.
Reactive oxygen species released from activated macrophages and neutrophils can damage cellular macromolecules in uninfected or non-damaged cells leading to necrosis of these cells (Ohshima et al. 2003) . Cell necrosis has been demonstrated to be a pro-inflammatory stimulus in that recognition of necrotic cell debris by macrophages leads to activation of pro-inflammatory cytokine signaling and amplification of the initial inflammatory response (Karin and Greten 2005) . Also, inflammation-mediated oxidative stress can potentiate inflammatory cytokine signaling since a number of pro-inflammatory signaling proteins can be regulated in a redoxsensitive fashion (Adachi et al. 2004; Kamata et al. 2005) .
Inflammation-mediated cell death has been demonstrated to play a role in the pathogenesis of acute liver injury following exposure to agents such as alcohol (Ceccanti et al. 2006) , pharmaceuticals (Jaeschke 2005) , and hepatotropic viruses (Choi and Ou 2006; Nakamoto and Kaneko 2003) . Immune-mediated liver disease is a serious human health problem since acute hepatitis may progress to chronic fibrosis and cirrhosis, a major risk factor for the development of hepatocellular carcinoma. Intravenous administration of ConA to mice has been developed as a model for T cell-mediated acute inflammatory liver injury in which hepatocytes are targeted by activated inflammatory cells (Tiegs et al. 1992) leading to hepatocyte apoptosis and necrosis.
While ConA has been shown to be toxic to primary mouse hepatocytes in cell culture (Leist and Wendel, 1996) , numerous studies have demonstrated the necessity of activated immune cells in the mechanism of ConA hepatotoxicity in vivo. Athymic mice and mice with severe combined immunodeficiency syndrome have been shown to be resistant to hepatotoxicity following ConA injection (Tiegs et al. 1992) . Additionally, administration of ConA to mice following depletion of either natural killer T cells (Takeda et al. 2000) , neutrophils (Bonder et al. 2004) or Kupffer cells (Schümann et al. 2000) failed to elicit hepatocyte death. Therefore, intravenous injection of ConA represents a useful animal model for investigating cytoprotective mechanisms against inflammatory liver injury since hepatocyte death is a direct consequence of immune system activation independent of any directly hepatotoxic chemical insult.
The Keap1-Nrf2 signaling pathway regulates the inducible expression of a battery of cytoprotective genes. Under basal conditions, Nrf2 is repressed through an interaction with Keap1 leading to proteasomal degradation of Nrf2 (Dinkova-Kostova et al. 2005) . However, exposure to both endogenous and exogenous reactive molecules such as reactive oxygen species, 15-deoxy-delta12,14-prostaglandin J 2 , dithiolethiones and triterpenoids leads to release of Nrf2 from Keap1 following modification of reactive cysteines within Keap1 or activation of pathways leading to phosphorylation of Nrf2 and disruption of the Keap1-Nrf2 interaction (Kobayashi and Yamamoto 2005) . Nrf2 can translocate to the nucleus and in combination with other transcription factors enhance the transcription of antioxidative genes, glutathione homeostasis genes and genes important for the production of reducing equivalents that collectively represent an adaptive response leading to protection against toxicity due to oxidative stress (Kwak et al. 2003; Motohashi et al. 2004; Osburn et al. 2006) . Therefore, the Nrf2-regulated adaptive response represents a potential target for attenuation of inflammation by protecting against inflammatory oxidative damage and pro-inflammatory redox-sensitive signaling. Indeed, the lack of an active Nrf2 signaling pathway in mice has been shown to result in increased inflammation and inflammation-mediated oxidative damage in a number of lung and colon disease models (Itoh et al. 2004; Khor et al. 2006; Osburn et al. 2007; Rangasamy et al. 2005; Thimmulappa et al. 2006) .
Recently, a hepatocyte-specific conditional Keap1 knockout (cKeap1-KO, AlbCre::Keap1(Flox/-)) mouse was developed in which the repression of Nrf2 signaling by Keap1 has been disrupted in hepatocytes leading to amplified Nrf2 signaling, constitutively enhanced expression of Nrf2-regulated cytoprotective genes and attenuated acetaminophen hepatotoxicity (Okawa et al. 2006) . Therefore, this model represents a genetic tool to investigate the effect of Nrf2-dependent cytoprotection on acute inflammatory liver injury, due to dampened Keap1 repression of Nrf2 signaling, without the post-natal lethality associated with systemic deletion of Keap1 . Additionally, administration of the synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im) represents a complementary pharmacological tool for examining the effect of activation of Nrf2 signaling on acute inflammatory liver injury since CDDO-Im administration has been shown to enhance expression of Nrf2-regulated cytoprotective genes in a number of organ systems (Yates et al. 2007) . Therefore, by comparing the severity of immune-mediated liver injury in mice with genetically and pharmacologically amplified Nrf2 signaling one can deduce the efficacy of hepatocyte-directed, Nrf2-dependent cytoprotection in attenuating hepatic inflammation.
In the present study, mice with hepatocyte-disrupted expression of Keap1, as well as Nrf2-WT mice but not Nrf2-KO mice pretreated with CDDO-Im, were resistant to ConA-mediated oxidative stress and hepatocyte necrosis. Genetic and pharmacological amplification of Nrf2 signaling had no effect on ConA-mediated serum pro-inflammatory soluble protein levels but inhibited later-phase hepatic inflammatory gene expression and inflammatory cell infiltration, apparently due to the abrogation of hepatocyte damage in these mice. Taken together, these results demonstrated that amplified Nrf2 signaling provides powerful protection against acute inflammatory liver injury by preventing inflammation-mediated hepatocyte necrosis leading to diminished proinflammatory gene expression and a cessation of the chronic inflammatory response to ConA administration.
Materials and Methods

Experimental animals
cKeap1-KO mice were generated by crossing Alb-Cre::Keap1(+/-) mice with Keap1(Flox/-) mice. Alb-Cre::Keap1(+/-) mice, Keap1(Flox/-) mice and AlbCre:Keap1(+/+) (cKeap1-WT) mice were generated on a C57BL/6J background (Okawa et al. 2006) . While this transgenic strategy results in knockout of Keap1 in hepatocytes, experimental evidence indicates hypomorphic Keap1 expression in other cell types (Melinda Yates, unpublished observation). Nrf2-KO mice on a C57BL/6J background were generated as previously described (Iida et al. 2004) . Nrf2-WT mice (C57BL/6J) were obtained from The Jackson Laboratory (Bar Harbor, ME). Genotypes were confirmed using PCR analysis of tail genomic DNA. 
Serum alanine aminotransferase (ALT) activity
ALT enzymatic activity of serum samples was determined using a Vet ACE® chemistry system (Alfa Wassermann, West Caldwell, NJ). Whole liver tissue was homogenized at a concentration of 0.1 g/ml in PBS containing 0.05% butylated hydroxytoluene and Complete protease inhibitor cocktail (Roche, Indianapolis, IN,) . Aconitase activity of liver homogenates was determined as previously described (Osburn et al. 2007) .
Aconitase activity
Lipid peroxidation
Lipid peroxidation products (malondialdehyde and 4-hydroxyalkenals in combination) in liver homogenates were detected using the Bioxytech LPO-586 kit (Oxis, Foster City, CA) using the methanesulfonic acid protocol according to the manufacturer's directions. the fragmentation reaction. The entire fragmentation product was then hybridized to the Affymetrix Mouse Genome 430 2.0 array chip for 18 hours. After 18 hours, the chips were removed, washed and stained using an Affymetrix GeneChip Fluidics Station 400.
Global gene expression analysis
The chips were then scanned using an Affymetrix GeneChip Scanner 3000 7G.
Pairwise comparisons of individual mice (n=3/group) were performed, generating 9
comparisons. Signal strength values were log-transformed to generate a normal distribution. Independent 2 sample t-tests were performed on the log-signal strength to determine differential expression between the two groups (p 0.05). To limit false positives, only genes with a 1.5-fold change or more and a comparison value of 6 or more were included. Affymetrix Analysis Center website was used for annotation of genes. The expression levels of selected genes were validated by quantitative RT-PCR.
Microarray data will be deposited in NCBI GEO upon acceptance of the manuscript.
Serum cytokine and chemokine analysis
Cytometric bead array was used to measure the serum levels of soluble proinflammatory proteins using the BD Cytometric Bead Array Mouse Inflammation Kit (BD Biosciences, San Jose, CA) according to manufacturer's directions. Flow cytometric analysis was performed using a FACS Calibur flow cytometer (BD Biosciences, San
Jose, CA). Data were acquired and analyzed using BD cytometric bead array software.
The concentration of interleukin-2 (IL-2) in serum was determined using an IL-2 ELISA Ready-Set-Go kit (eBiosciences, San Diego, CA) according to manufacturer's directions. Non-detect values were assigned a concentration equal to the lowest detected value divided by the square root of two. 
Hepatic macrophage accumulation
Four µm-thick tissue sections cut from formalin-fixed paraffin-embedded tissue blocks were deparaffinized and rehydrated. Sections were blocked with 5% goat serum and 1% bovine serum albumin and incubated with biotinylated Griffonia simplificifolia Lectin I (1:50, Vector Laboratories, Burlingame, CA). Endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxide and lectin binding was detected using horseradish peroxidase conjugated strepavidin (1:250, Invitrogen, Carlsbad, CA) followed by visualization using SIGMAFAST ™ 3,3 -diaminobenzidine (Sigma-Aldrich, St.
Louis, MO). Sections were counterstained with hematoxylin, dehydrated through alcohol and mounted. Positively stained macrophages were manually counted at 400X magnification across six random fields.
Hepatic neutrophil accumulation
Four µm-thick tissue sections cut from formalin-fixed paraffin-embedded tissue blocks were deparaffinized and rehydrated. Neutrophils were stained using a naphthol AS-D chloroacetate (Specific Esterase) kit (Sigma-Aldrich, St. Louis, MO) according to the manufacturer's directions. Sections were counterstained with haematoxylin and mounted. Positively stained neutrophils were manually counted at 400X magnification across six random fields.
Cytokine gene expression
Total RNA was extracted from liver tissue using Versagene RNA purification columns (Gentra, Minneapolis, MN) according to manufacturer's directions. 1 µg of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 cDNA was synthesized from 1 µg of mRNA using the iScript cDNA synthesis kit (BioRad, Hercules, CA, USA). Quantitative RT-PCR analysis was performed using IQ Sybr Green supermix. Previously published primer pairs for Hypoxanthine-guanine phosphoribosyltransferase (Osburn et al. 2006) , interferon (IFN ) (Overbergh et al. 1999) , tumor necrosis factor (TNF ) (Overbergh et al. 1999) , monocyte chemoattractant protein-1 (MCP-1) (Hagen et al. 2007) , and macrophage inflammatory protein-2 (MIP-2) (Fadl et al. 2007) were synthesized and used for specific gene expression analysis. Melting curve analysis was used to assess amplification specificity.
Standard curves using serial dilutions of cDNA were generated for each gene in order to determine amplification efficiency and relative quantification was calculated using the method of Pfaffl (Pfaffl 2001) .
Statistical analysis
Student's t-test, for comparison of two groups, or ANOVA with Student-Neuman Kuels multiple comparison analysis, for comparison of three or more groups, was used to evaluate statistically significant differences.
Results
Genetic and pharmacological amplification of Nrf2 signaling in hepatocytes prevents acute inflammatory liver injury
Histological analysis of liver and determination of serum ALT values was performed in order to assess the protective effect of genetic amplification of Nrf2 signaling and CDDO-pretreatment on immune-mediated hepatotoxicity. Microscopic examination of H&E stained liver sections revealed severe and extensive necrosis in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 livers from cKeap1-WT but not cKeap1-KO mice 24-hr following ConA challenge ( Figure   1a ). Likewise, markedly increased serum ALT values were detected in cKeap1-WT mice but not cKeap1-KO mice following ConA administration. At the same time, CDDO-Im pretreatment also inhibited ConA-mediated hepatotoxicity, apparently in an Nrf2-dependent fashion. Severe and extensive necrosis was observed in vehicle-pretreated but not CDDO-Im pretreated Nrf2-WT mice 24-hr following ConA challenge (Figure 1b 
Amplified Nrf2 signaling inhibits ConA-mediated oxidative damage
Since reactive oxygen species released from activated inflammatory cells can contribute to acute inflammatory liver injury, we analyzed the hepatic levels of two indicators of oxidative damage, 24-hr following ConA administration. Aconitase specific activity was measured as an indicator of protein oxidation since exposure of aconitase to reactive oxygen species results in reduction of ferric iron to ferrous iron, release of This analysis identified 590 Nrf2-dependent genes, including Nrf2 (Nfe2l2, fold-change, 1.6). For example, increased basal expression of antioxidative genes, such as Gpx2
(fold-change, 20.9) and Txnrd1 (2.4), as well as xenobiotic metabolism and glutathione homeostasis genes was detected in livers of cKeap1-KO mice relative to control mice ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 immune response, cellular growth and proliferation, gene expression, carbohydrate metabolism and cell cycle (data not shown). Despite the broad impact of Keap1 disruption on gene expression, it is likely that enhanced expression of Nrf2-regulated antioxidative genes in cKeap1-KO mice and CDDO-Im pretreated Nrf2-WT mice prevented macromolecular oxidation during ConA-mediated inflammation.
Amplification of Nrf2 signaling has no effect on early-phase soluble proinflammatory protein secretion A possible explanation for the decreased immune-mediated liver injury in cKeap1-KO mice is that hepatocyte-specific deletion of Keap1, perhaps coupled with hypomorphic knockdown of Keap1 in other tissues, inhibited the initiation of the inflammatory response triggered by ConA injection. To address this possibility, the levels of soluble pro-inflammatory proteins in serum, 3-hr following ConA administration, were assessed to determine whether early-phase ConA-mediated pro-inflammatory cytokine/chemokine profiles were affected by amplification of Nrf2 signaling. Disruption of Keap1 had no effect on ConA-mediated cytokine or chemokine secretion as the serum concentrations of interferon (IFN ), tumor necrosis factor (TNF ), monocyte chemoattractant protein (MCP-1) and interleukin-2 (IL-2) were similar in cKeap1-WT and cKeap1-KO mice following ConA administration (Figure 3) . Therefore, the protection afforded by disruption of Keap1 was directly due to Nrf2-dependent cytoprotection.
Conversely, CDDO-Im pretreatment resulted in decreased serum concentrations (pg/ml, mean ± SEM) of the pro-inflammatory mediators IFN (75%, vehicle-pretreated (Figure 4) . At the same time, CDDO-Im pretreatment had no effect on MCP-1 and IL-2 secretion as the serum concentrations of these proteins were similar in vehicle-pretreated Nrf2-WT and CDDO-Im pretreated Nrf2-WT mice. 
Late-phase hepatic inflammatory cell infiltration is attenuated by disruption of
Keap1 and CDDO-Im pretreatment
The accumulation of hepatic macrophages and neutrophils 24-hr following ConA challenge was quantified to assess whether attenuation of late-phase hepatic inflammatory cell infiltration contributed to the protection afforded by genetic and pharmacological amplification of Nrf2 signaling. Lectin labeling of hepatic macrophages (Table 2) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 diminishing the pro-inflammatory stimulus in the liver resulting in decreased infiltration of inflammatory cells.
Discussion
Investigation of protective mechanisms against immune-mediated cell death can identify opportunities for the development of preventive strategies to block the progression of acute hepatitis to chronic hepatic inflammatory disease. This study demonstrated that amplification of Nrf2 signaling in hepatocytes is sufficient for attenuation of acute inflammatory liver injury. Enhanced Nrf2 signaling in hepatocytes led to elevated expression of antioxidative genes, thereby abrogating inflammationassociated oxidative stress and inhibiting hepatocyte necrosis. Interestingly, even though disruption of Keap1 had no effect on early-phase serum levels of soluble proinflammatory proteins; late-phase hepatic pro-inflammatory gene expression was substantially lower in cKeap1-KO mice compared to cKeap1-WT mice resulting in decreased accumulation of macrophages and neutrophils in livers following ConA challenge. Therefore, genetic amplification of Nrf2 signaling in hepatocytes had no effect on the initial immune response triggered by ConA injection, but instead resulted in striking protection against the subsequent inflammation-mediated hepatotoxicity and attendant additional hepatic inflammation.
Conversely, CDDO-Im pretreatment attenuated early-phase serum levels of soluble pro-inflammatory proteins in both Nrf2-WT mice and Nrf2-KO mice. However, this partially suppressed inflammatory response was nonetheless sufficiently robust to result in substantial hepatotoxicity in mice lacking functional Nrf2 signaling. Yates, et al (Yates et al. 2006) have previously demonstrated that pretreatment of Nrf2-WT mice but 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 not Nrf2-KO mice results in increased expression of antioxidative genes in the liver. Therefore, the protective effect of CDDO-Im pretreatment can be attributed to enhanced expression of Nrf2-regulated cytoprotective genes in hepatocytes rather than impairment of T-cell activation and signaling. CDDO-Im pretreatment of Nrf2-WT mice also inhibited hepatic late-phase pro-inflammatory gene expression and inflammatory cell infiltration. Therefore, pharmacological activation of Nrf2 signaling mirrored genetic amplification by also effectively attenuating inflammation-mediated hepatotoxicity and preventing additional hepatic inflammation.
One plausible explanation for these observed outcomes in these two models of Nrf2 manipulation is the absence of inflammation-mediated hepatocyte necrosis in cKeap1 and CDDO-Im pretreated Nrf2-WT mice resulted in decreased activation of proinflammatory gene expression in macrophages and subsequent diminution of inflammatory cell infiltration in the liver. The presence of necrotic cell debris activates inflammatory signaling in macrophages. Maeda, et al(Maeda et al. 2005) reported that exposure of primary macrophages to a necrotic cell supernatant activated the proinflammatory transcription factor nuclear factor-kB (NF-kB). Additionally, high mobility group box 1 protein, a chromatin binding protein released from necrotic cells, has been shown to bind to Toll-like receptors 2 and 4 on macrophages resulting in NF-kB activation (Park et al. 2006) and TNF release (Scaffidi et al. 2002) . NF-kB also regulates the expression of MCP-1 (Ueda et al. 1997) , a macrophage chemokine, and MIP-2 (Lee et al. 2005 ) , a neutrophil chemokine, in macrophages. The hepatic expression of these chemokines was diminished in the current study in cKeap1-KO mice and CDDO-Im pretreated Nrf2-WT mice. Therefore, we speculate that up-regulation of Nrf2-regulated 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 cytoprotective enzymes enhanced hepatocyte survival resulting in decreased production of necrotic cell debris and subsequent recognition by macrophages. This effect would serve to reduce inflammatory cell infiltration in the liver, thereby blocking a continued inflammatory response to the initial ConA challenge.
Attenuation of hepatic inflammatory responses through direct modulation of the immune system has been shown to inhibit acute inflammatory liver injury. Depletion of neutrophils (Bonder et al. 2004) and Kupffer cells (Schümann et al. 2000) provided substantial protection against ConA-mediated liver injury. Diminished acute inflammatory liver injury has also been demonstrated in mice lacking T cells (Tiegs et al. 1992 ) and natural killer T cells (Takeda et al. 2000) . Additionally, the administration of immunomodulatory agents, such as pentoxifylline (Fukuda et al. 2005 ) and anti-TNF (Fukuda et al. 2005 ) , has been shown to provide protection against ConAmediated inflammatory liver injury in mice. Current therapeutic options for treating acute inflammatory liver injury in humans involve the administration of immunomodulatory agents. However, the use of these agents is associated with a number of adverse effects due to the non-specific nature of their mechanism of action (Fantini et al. 2006) .
The current study highlights an approach that acts independently of immunomodulation but instead relies on activation of cellular defenses in parenchymal cells to combat nonspecific inflammation-mediated destruction of normal tissue. Therefore, this approach might be expected to result in fewer side effects than traditional immunomodulatory therapies since the blunting of inflammation can be attributed to blocking the stimulus that is prolonging the inflammatory response without directly affecting initial proinflammatory signaling. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 In summary, the current study clearly demonstrated the importance of Nrf2 signaling for protection against acute inflammatory liver injury. Nrf2-dependent upregulation of cytoprotective enzymes in the target organ of the ConA-mediated inflammatory response resulted in profound protection against immune-mediated hepatitis by preventing hepatocyte necrosis and subsequent amplification of the inflammatory response. Inflammatory liver injury represents a serious burden to human health in that progression of acute inflammatory liver injury to chronic inflammatory liver disease increases risk of liver cancer. In fact, hepatocellular carcinoma due to cirrhosis, an end-stage liver disease that may develop from chronic hepatitis due to either chronic alcohol consumption or hepatitis B or C infection, accounts for nearly 80% of all liver cancer cases (Kensler et al. 2003) . Therefore, the development of strategies designed to block the progression of acute inflammatory liver injury to chronic inflammatory diseases would prove beneficial to ameliorating the burden of liver cancer in human populations.
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Collectively, the current study identifies targeting the Nrf2 signaling pathway with inducers such as triterpenoids to bolster the cell survival defenses of uninfected or nondamaged cells as a potentially powerful mechanism for attenuation of acute inflammatory injury that may complement current therapeutic strategies of diminishing pro-inflammatory signaling.
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